Nafiseh Sadat Alizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nafiseh Sadat Alizadeh has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Teymouri
Department of Physical Medicine and Rehabilitation, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Behnam Behnoush
Department of Forensic Medicine, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication - Mahsa Panahishokouh
Department of Clinical Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication - Mehrnoush Dianatkhah
Clinical Education Department, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
1 shared publication - Mina Borran
Department of Internal Medicine, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran
1 shared publication - Neda Faraji
Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 14 September 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (9) , e1509
Vitamin B12 effectiveness in the management of hospitalized COVID‐19 and its clinical outcomes and complications: A randomized clinical trial
Background and Aims: Since 2019, severe acute respiratory syndrome coronavirus 2, has spread and challenged the health care system for treatment which is mainly limited to supportive care. It is well‐established that malnutrition impedes the immunity in human bodies, and makes it vulnerable to microorganisms. Vitamin B12 is one of the agents that has critical roles in body systems. Thus, the following clinical trial was conducted to assess its possible therapeutic value in COVID‐19 patients.Method: The present randomized clinical trial was carried out in Baharlou Hospital, and patients with confirmed COVID‐19 infection within 24 h of admission were included. We used quadruple blocks randomization to divide patients into groups of case and control. The case group received 1000 mg of vitamin B12, daily for 7 day while the patients in control group were administered distilled water as placebo. The studied outcomes were duration of hospitalization, need for intensive care unit (ICU), mechanical ventilation, mortality rate and laboratory findings. The statistical analysis was done via SPSS version 22.Results: After implementing inclusion and exclusion criteria, 34 participants were included in the study, 20 of which were male. Serum levels of creatinine, LDH (Lactate dehydrogenase), Ferritin, and CRP (C‐reactive protein) had decreased in both groups. The improving changes of CRP, LDH, ferritin and creatinine was higher in case group. The increase of Alanine Transaminase and D‐dimer was higher in control group. however there was no statistically significant difference. More patients were admitted to ICU in the control group but the difference was not statistically significant. Duration of hospitalization did not differ statistically between the groups. No in hospital mortality has been recorded.Conclusion: Our study suggests that vitamin B12 supplementation seem to have curative effect in COVID‐19. Nutritious diet is necessary for proper functioning of the immune system. Since malnutrition is associated with poor prognosis in COVID‐19 patients, and limited number of participants in this study, we suggest performing meta‐analysis on similar studies to reach reliable result.
- 14 September 2023
- Published by Wiley in Health Science Reports
- Vol. 6 (9) , e1509
Open AccessVitamin B12 effectiveness in the management of hospitalized COVID‐19 and its clinical outcomes and complications: A randomized clinical trial
Background and Aims: Since 2019, severe acute respiratory syndrome coronavirus 2, has spread and challenged the health care system for treatment which is mainly limited to supportive care. It is well‐established that malnutrition impedes the immunity in human bodies, and makes it vulnerable to microorganisms. Vitamin B12 is one of the agents that has critical roles in body systems. Thus, the following clinical trial was conducted to assess its possible therapeutic value in COVID‐19 patients.Method: The present randomized clinical trial was carried out in Baharlou Hospital, and patients with confirmed COVID‐19 infection within 24 h of admission were included. We used quadruple blocks randomization to divide patients into groups of case and control. The case group received 1000 mg of vitamin B12, daily for 7 day while the patients in control group were administered distilled water as placebo. The studied outcomes were duration of hospitalization, need for intensive care unit (ICU), mechanical ventilation, mortality rate and laboratory findings. The statistical analysis was done via SPSS version 22.Results: After implementing inclusion and exclusion criteria, 34 participants were included in the study, 20 of which were male. Serum levels of creatinine, LDH (Lactate dehydrogenase), Ferritin, and CRP (C‐reactive protein) had decreased in both groups. The improving changes of CRP, LDH, ferritin and creatinine was higher in case group. The increase of Alanine Transaminase and D‐dimer was higher in control group. however there was no statistically significant difference. More patients were admitted to ICU in the control group but the difference was not statistically significant. Duration of hospitalization did not differ statistically between the groups. No in hospital mortality has been recorded.Conclusion: Our study suggests that vitamin B12 supplementation seem to have curative effect in COVID‐19. Nutritious diet is necessary for proper functioning of the immune system. Since malnutrition is associated with poor prognosis in COVID‐19 patients, and limited number of participants in this study, we suggest performing meta‐analysis on similar studies to reach reliable result.
- Open Access
- 14 September 2021
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 28 (1) , 166-169
Metronidazole induced anaphylactic shock: a case report
Metronidazole induced anaphylactic shock is an extremely rare drug reaction. We reported a 39-year-old man with severe anaphylactic shock caused by Metronidazole. He denied history of food or drugs allergy. Severe cardiovascular collapse suddenly occurred after receiving intravenous Metronidazole. The patient was successfully managed as a case of anaphylactic shock and finally discharge.
- 14 September 2021
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 28 (1) , 166-169
Open AccessMetronidazole induced anaphylactic shock: a case report
Metronidazole induced anaphylactic shock is an extremely rare drug reaction. We reported a 39-year-old man with severe anaphylactic shock caused by Metronidazole. He denied history of food or drugs allergy. Severe cardiovascular collapse suddenly occurred after receiving intravenous Metronidazole. The patient was successfully managed as a case of anaphylactic shock and finally discharge.